EUCAIM announces key partnerships to accelerate Cancer Research in Europe

EUCAIM is pleased to announce the signing of two significant Memoranda of Understanding (MoUs) and a Data Share Agreement (DSA), marking a milestone in collaborative efforts to advance cancer research in Europe.

Memorandum of Understanding with EOSC4Cancer and GDI

EUCAIM has signed an MoU with EOSC4Cancer and the Genomic Data Infrastructure (GDI) with the goal of stimulating mutually beneficial exchanges to advance Life Sciences research in Europe, with a specific focus on cancer research.

EOSC4Cancer is a project designed to make a diverse array of cancer-related data accessible. This includes data from genomics, imaging, medical, clinical, environmental, and socio-economic sources. The project aims to enhance and use federated and interoperable systems to securely identify, share, process, and reuse FAIR data across borders. The well-curated datasets provided by EOSC4Cancer will be essential for reproducible and robust analytics and computational methods, including machine learning and artificial intelligence. The project encompasses five use cases that cover the entire patient journey, from cancer prevention and diagnosis to treatment.

The GDI project aims to enhance access to genomic and related phenotypic and clinical data to advance research, policymaking, and healthcare throughout Europe. By unlocking a network of over one million genome sequences, GDI will provide significant opportunities for transnational and multi-stakeholder actions in personalized medicine. This includes applications in cancer, common, rare, and infectious diseases. Additionally, the project will offer access to a reference genome collection representing the European population, known as the Genome of Europe.

For EUCAIM, these partnerships will enable coordinated efforts towards the discovery, access, and sharing of cancer-related research data.

Data Share Agreement with INCISIVE

In addition to the MoUs, EUCAIM has signed a DSA with the INCISIVE project. This agreement outlines the terms and conditions for sharing, managing, and accessing the INCISIVE Data after its completion.

This agreement ensures the continued availability and enhancement of INCISIVE’s valuable data resources, supporting ongoing cancer research and technological development within the EUCAIM framework.

These key partnerships underscore EUCAIM’s commitment to fostering collaboration and innovation in cancer research. EUCAIM is excited about the potential of these collaborations to drive significant advancements in cancer research and looks forward to the positive impact these partnerships will have on the scientific community and patients across Europe.

Join the EUCAIM Consortium

Open Call for New Beneficiaries

We’re inviting new partners to enhance our pan-European infrastructure for cancer images and artificial intelligence.

Whether you’re a data holder with valuable cancer images or an innovator developing AI tools for precision medicine, this is your chance to contribute to a groundbreaking project.

Apply by 10 June 2024!

Open Call Webinar

We recently hosted a webinar with more details for prospective applicants to the open call. A recording is available.

Our open Call for new collaborators
launches in April 2024

Opportunities for data holders & AI developers to contribute await! Let‘s join forces to enhance cancer diagnosis and treatment

Be the first to know and apply!

SAVE THE DATE
March 14, 10:00-11:30 aM CET

DISCOVER THE CANCER IMAGE EUROPE PLATFORM

TECHNICAL DEMONSTRATION WEBINAR

Explore the potential for AI-driven cancer care advancements!
Learn how to access and utilize our federated cancer image repository. The webinar is for AI Innovators & Data Providers interested in the platform and will feature an introduction to EUCAIM & Cancer Image Europe and a demonstration of data exploration & access.

Survey Invitation

Join Leading Experts In Shaping AI In Cancer

EUCAIM is looking for your feedback! We have recently published a Stakeholder Survey in order to reach out to potential end-users and stakeholders. We believe that your insights could significantly contribute to understanding the expectations of potential users and identifying the essential aspects that stakeholders find crucial for future engagement and collaboration with the platform.

Therefore, we would like to invite you to participate in the Stakeholder Survey about the Cancer Image Europe platform.

Completing the survey will take approximately 10 minutes. Your participation is crucial to the success of this project, and we deeply appreciate your expertise in shaping the future of cancer imaging and treatment.